SAA1 alleles as risk factors in reactive systemic AA amyloidosis - PubMed (original) (raw)
SAA1 alleles as risk factors in reactive systemic AA amyloidosis
D R Booth et al. Amyloid. 1998 Dec.
Abstract
SAA1 is the predominant isoform of acute phase human SAA deposited as AA amyloid fibrils in reactive systemic amyloidosis. It has recently been reported that in the Japanese population, in whom the SAA1 gamma allele occurs with a frequency of 37%, possession of, and especially, homozygosity for this allele is a significant risk factor for AA amyloidosis in adult patients with rheumatoid arthritis (RA). In contrast we report here that in a control sample of 95 healthy adult male Caucasians the SAA1 gamma allele occurs at the much lower frequency of 5.3% and that, among 41 patients with juvenile chronic arthritis (JCA) and AA amyloidosis, there was a highly significantly increased frequency of the SAA1 alpha allele (90.2%), and particularly homozygosity for this allele (80.5%), compared both to the healthy controls (75.8% and 57.9% respectively) and to 8 JCA cases without amyloid (56.3% and 12.5%). A similar trend with respect to frequency of the SAA1 alpha allele and homozygosity for it was observed among 26 adult Caucasian RA patients with AA amyloid and 26 such cases without amyloid, although it did not reach statistical significance. These results suggest that there is probably differential amyloidogenicity amongst the different SAA1 isoforms and indicate that homozygosity for SAA1 alpha and SAA1 gamma in the different populations is a significant risk factor for development of AA amyloidosis. In Caucasian patients with JCA, the presence of the homozygous SAA1 alpha genotype indicates high risk of amyloidosis and should encourage early and aggressive anti-inflammatory therapy to keep circulating SAA levels as low as possible.
Similar articles
- A novel allelic variant of serum amyloid A, SAA1 gamma: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis.
Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, Tsutsui Y, Shirasawa H. Baba S, et al. Hum Mol Genet. 1995 Jun;4(6):1083-7. doi: 10.1093/hmg/4.6.1083. Hum Mol Genet. 1995. PMID: 7655463 - Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis.
Moriguchi M, Terai C, Koseki Y, Uesato M, Nakajima A, Inada S, Nishinarita M, Uchida S, Nakajima A, Kim SY, Chen CL, Kamatani N. Moriguchi M, et al. Hum Genet. 1999 Oct;105(4):360-6. doi: 10.1007/s004399900150. Hum Genet. 1999. PMID: 10543406 - An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians.
Yamada T, Okuda Y, Takasugi K, Wang L, Marks D, Benson MD, Kluve-Beckerman B. Yamada T, et al. Amyloid. 2003 Mar;10(1):7-11. doi: 10.3109/13506120308995250. Amyloid. 2003. PMID: 12762135 - Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis.
Nakamura T. Nakamura T. Mod Rheumatol. 2008;18(2):109-18. doi: 10.1007/s10165-008-0035-2. Epub 2008 Mar 4. Mod Rheumatol. 2008. PMID: 18369528 Review. - AA amyloidosis: basic knowledge, unmet needs and future treatments.
Obici L, Merlini G. Obici L, et al. Swiss Med Wkly. 2012 May 31;142:w13580. doi: 10.4414/smw.2012.13580. eCollection 2012. Swiss Med Wkly. 2012. PMID: 22653707 Review.
Cited by
- Uncovering the knowledge about systemic amyloidosis relevant to the rheumatologists.
Pereira IA, Neto NSR, do Nascimento RRNR, Freire EAM, Neves FS, Bica BERG, Pinheiro FAG, Perazzio SF, Cordeiro RA, Giardini HAM, Azevedo VF, Sztajnbok FR. Pereira IA, et al. Adv Rheumatol. 2024 Sep 16;64(1):71. doi: 10.1186/s42358-024-00399-3. Adv Rheumatol. 2024. PMID: 39285267 Review. - AA Amyloidosis: A Contemporary View.
Mirioglu S, Uludag O, Hurdogan O, Kumru G, Berke I, Doumas SA, Frangou E, Gul A. Mirioglu S, et al. Curr Rheumatol Rep. 2024 Jul;26(7):248-259. doi: 10.1007/s11926-024-01147-8. Epub 2024 Apr 3. Curr Rheumatol Rep. 2024. PMID: 38568326 Free PMC article. Review. - Gastric perforation caused by secondary systemic amyloidosis.
Yamamoto H, Yokota A, Suzuki N, Tachibana M, Tsutsumi Y. Yamamoto H, et al. Clin Case Rep. 2021 May 24;9(5):e04254. doi: 10.1002/ccr3.4254. eCollection 2021 May. Clin Case Rep. 2021. PMID: 34084518 Free PMC article. - Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker.
Sorić Hosman I, Kos I, Lamot L. Sorić Hosman I, et al. Front Immunol. 2021 Feb 19;11:631299. doi: 10.3389/fimmu.2020.631299. eCollection 2020. Front Immunol. 2021. PMID: 33679725 Free PMC article. Review. - Development of quantitative mass spectrometric immunoassay for serum amyloid A.
Trenchevska O, Yassine HN, Borges CR, Nelson RW, Nedelkov D. Trenchevska O, et al. Biomarkers. 2016 Dec;21(8):743-751. doi: 10.1080/1354750X.2016.1201533. Epub 2016 Jul 22. Biomarkers. 2016. PMID: 27308834 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous